Can chronic therapeutic drug use by the elderly affect Alzheimer’s disease risk and rate of progression?
Rafael Franco , Joan Serrano-Marín
Exploration of Neuroprotective Therapy ›› 2023, Vol. 3 ›› Issue (1) : 8 -23.
There is no approved drug capable of halting the progression of the most prevalent neurodegenerative disorders, namely Alzheimer’s disease (AD) and Parkinson’s disease (PD). Current therapeutic strategies focus mainly on the inhibition of the formation of protein aggregates and their deposition in the central nervous system. However, after almost a hundred years, proper management of the disease is still lacking. The fact of not finding effective management tools in the various clinical trials already carried out suggests that new hypotheses and strategies should be explored. Although vast resources have been allocated to the investigation of protein aggregates and the pathophysiology is now better understood, clues to the actual etiology are lacking. It is well known that brain homeostasis is of paramount importance for the survival of neurons. Drugs that target the periphery are often not subject to evaluation for their potential effect on the central nervous system. While acute treatments may be irrelevant, pills used for chronic conditions can be detrimental to neurons, especially in terms of progressive damage leading to a long-term decline in neuronal survival. Due to the lack of advances in the search for a curative treatment for neurodegenerative diseases, and the lack of new hypotheses about their etiology, a novel hypothesis is here proposed. It consists of assuming that the effects of the drugs most commonly used by the elderly, such as antihypertensive, hypoglycemic, and hypocholesterolemic, could have a negative impact on neuronal survival.
Diabetes / hypercholesterolemia / chronic diseases / overmedication / hypertension / cerebral blood flow / neurodegenerative diseases / musicians
| [1] |
GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019; 18: 88-106. |
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
Vaquero L, Hartmann K, Ripollés P, Rojo N, Sierpowska J, François C, |
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
Franco R. Coffee and mental health. Aten Primaria. 2009; 41: 578-81. |
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
Nehlig A. Effects of coffee/caffeine on brain health and disease: what should I tell my patients? Pract Neurol. 2016; 16: 89-95. |
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
McPherson RA, Pincus MR. Henry’s clinical diagnosis and management by laboratory methods. 22nd ed. Philadelphia: Saunders; 2011. |
| [56] |
|
| [57] |
Fong CW. Statins in therapy: understanding their hydrophilicity, lipophilicity, binding to 3-hydroxy-3-methylglutaryl-CoA reductase, ability to cross the blood brain barrier and metabolic stability based on electrostatic molecular orbital studies. Eur J Med Chem. 2014; 85: 661-74. |
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
Kawas C, Corrada M, Paganini-Hill A, |
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
Utermann G. The apo E-system: genetic control of plasma lipoprotein concentration. Adv Exp Med Biol. 1986; 201: 261-72. |
| [67] |
|
| [68] |
|
| [69] |
|
| [70] |
|
| [71] |
Wang W, Zhao F, Ma X, Perry G, |
| [72] |
|
| [73] |
|
| [74] |
|
| [75] |
|
| [76] |
|
| [77] |
Brian D. Occam’s razor [Internet]. Encyclopedia Britannica; [cited 2023 Jan 24]. Available from: https://www.britannica.com/topic/Occams-razor |
| [78] |
Essential hypotension. JAMA. 1925; 84: 896-7. |
| [79] |
|
| [80] |
Goldner JA. Metoprolol-induced visual hallucinations: a case series. J Med Case Rep. 2012; 6: 65. |
| [81] |
|
| [82] |
|
| [83] |
|
| [84] |
|
| [85] |
|
| [86] |
|
| [87] |
|
| [88] |
|
| [89] |
|
| [90] |
|
| [91] |
|
| [92] |
|
| [93] |
|
| [94] |
|
| [95] |
Trenkwalder P. Potential for antihypertensive treatment with an AT1-receptor blocker to reduce dementia in the elderly. J Hum Hypertens. 2002; 16: S71-5. |
| [96] |
|
| [97] |
|
| [98] |
|
| [99] |
|
| [100] |
|
| [101] |
|
| [102] |
|
| [103] |
|
| [104] |
|
| [105] |
|
| [106] |
|
| [107] |
|
| [108] |
|
/
| 〈 |
|
〉 |